Clarivate opened lower at $2.29, compared with its previous close of $2.32. In the last trading session, the stock traded between $2.26 and $2.42. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Clarivate is now worth
$ 10.15
Resulting in a loss of
$ 89.85 (89.85%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.02 (-0.69%)
Day High
$2.42
Day Low
$2.26
Day Open
$2.29
Prev Close
$2.32
Volume
25,96,647
1W Return
9.09%
1M Return
43.55%
3M Return
20.25%
6M Return
-17.42%
1Y Return
-35.64%
Market Cap ($ Mn)
1,474
PE Ratio
-
PB Ratio
0.28
PEG Ratio
-
ROE
-4.04%
ROCE
0.73%
EPS (TTM)
$-0.13
1 Week
9.09%
1 Month
43.55%
3 Months
20.25%
6 Months
-17.42%
9 Months
27.29%
Clarivate Q3FY26 Results: Organic ACV up 1.8% as Life Sciences sale completes
Organic ACV grew 1.8% YoY, with recurring organic revenue up 1.3%. Completed sale of Life Sciences and Healthcare segment ahead of schedule. Repurchased $293 million of debt year-to-date; plans further reduction. IP segment ACV returned to positive growth for first time in three years. FY26 GAAP EPS guidance remains at $(0.65)-$(0.62), below consensus.
9 days agoClarivate enters partnership with Sterne Kessler to develop AI patent tools
Clarivate Plc and Sterne Kessler announced a co-development partnership for AI-enhanced patent workflow solutions. The collaboration combines Sterne Kessler’s practitioner-built technology with Clarivate’s IP data and software. Initial release targeting patent drafting workflow enhancements in Rowan Patents is planned for H1 2027.
28 days agoClarivate sets pricing for $75 million debt tender offer
Clarivate Plc capped its debt tender offer at $75 million for 3.875% Senior Secured Notes due 2028. Total consideration set at $975.15 per $1,000 principal amount with a +50 bps fixed spread. Reference yield determined at 4.864% based on market data from September 23, 2026. Settlement date expected on September 25, 2026, subject to standard conditions.
1mo agoClarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Clarivate Plc announced on Aug. 6, 2026, the expansion of agentic AI capabilities across its Cortellis portfolio, covering drug discovery, safety assessment, and competitive intelligence. The new features span Cortellis Drug Discovery Intelligence, OFF-X, and Cortellis Competitive Intelligence, embedding AI into existing R&D workflows to reduce manual effort and accelerate decision-making. Anne Lecocq, Senior Vice President and General Manager, R&D, Life Sciences & Healthcare at Clarivate, described the development as Cortellis evolving into a connected ecosystem of agentic capabilities built on trusted data. The expansion reflects Clarivate's strategy of integrating AI-driven intelligence across the full drug development lifecycle.
3mo agoClarivate FY26 Results: GAAP EPS guidance cut to $(0.64)-$(0.54)
Clarivate cuts FY2026 GAAP EPS guidance to $(0.64)-$(0.54), widening losses from prior $(0.29)-$(0.19) range and missing $(0.17) analyst estimates.
3mo agoClarivate appoints Michael Easton as CFO effective August 8
Clarivate Plc announced the appointment of Michael Easton as EVP and CFO, succeeding Jonathan Collins. Effective August 8, 2026, Easton will lead financial strategy, focusing on growth and capital allocation.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $521.13 | -2.26% | $38,69,975.87M | 28.61 | |
| $172.40 | +2.12% | $3,97,675.94M | 160.64 | |
| $128.38 | +8.82% | $3,88,187.23M | 25.87 | |
| $234.10 | +0.15% | $2,87,592.79M | 28.43 | |
| $334.47 | +2.49% | $2,73,854.67M | 323.12 | |
| $248.22 | +1.51% | $2,34,597.93M | 20.94 | |
| $229.06 | +1.46% | $2,34,542.55M | 3,970.91 | |
| $149.26 | +1.81% | $1,80,374.29M | 103.31 | |
| $218.01 | +2.12% | $1,79,422.23M | 23.42 | |
| $253.66 | -1.88% | $1,49,846.35M | 15.14 | |
| $70.68 | +0.90% | $1,44,321.35M | 17.29 | |
| $306.36 | +0.30% | $1,20,938.37M | 26.28 |
An investment of $100 made 5 years ago in Clarivate is now worth
$ 10.15
Resulting in a loss of
$ 89.85 (89.85%)
Note: Past profits do not guarantee future returns.
